Shares of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) hit a new 52-week high during mid-day trading on Thursday . The company traded as high as $4.49 and last traded at $4.30, with a volume of 231,104 shares. The stock had previously closed at $4.12.

AUPH has been the subject of a number of research analyst reports. HC Wainwright initiated coverage on shares of Aurinia Pharmaceuticals in a research report on Thursday, June 30th. They set a “buy” rating and a $7.00 price objective for the company. Canaccord Genuity set a $10.00 price objective on shares of Aurinia Pharmaceuticals and gave the stock a “buy” rating in a research report on Friday, August 5th. Zacks Investment Research cut shares of Aurinia Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Thursday, May 5th. Finally, Leerink Swann reaffirmed an “outperform” rating and set a $7.00 price objective on shares of Aurinia Pharmaceuticals in a research report on Wednesday, July 6th. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. The stock has an average rating of “Buy” and an average price target of $7.15.

The company’s market capitalization is $138.51 million. The firm has a 50-day moving average price of $3.12 and a 200-day moving average price of $2.75.

Aurinia Pharmaceuticals Inc is a Canada-based clinical-stage biopharmaceutical company operating in the field of nephrology and autoimmunity. The Company’s primary business is the development of a therapeutic drug to treat autoimmune diseases, in particular lupus nephritis (LN). It is focused on the development of its lead compound voclosporin, a therapeutic immunomodulating drug candidate, which is a second-generation calcineurin inhibitors (CNI) to treat patients afflicted with LN.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.